Literature DB >> 30973964

Prevalence of fibromyalgia among women with deep infiltrating endometriosis.

Jose Luis Coloma1, Maria-Angeles Martínez-Zamora1,2,3, Antonio Collado4, Meritxell Gràcia1, Mariona Rius1, Lara Quintas1, Francisco Carmona1,2,3.   

Abstract

OBJECTIVE: To estimate the prevalence of fibromyalgia among women with endometriosis and analyze the effect of fibromyalgia on health-related quality of life (HRQoL).
METHODS: An observational case-control study conducted at a tertiary hospital in Barcelona between April 2015 and March 2017 among women with deep infiltrating endometriosis (DIE; n=80), women with superficial endometriosis or ovarian endometrioma (non-DIE; n=76), and control women without endometriosis (n=73). Fibromyalgia was assessed via the London Fibromyalgia Epidemiological Study Screening Questionnaire (LFESSQ). HRQoL was evaluated with the 36-Item Short Form (SF-36) questionnaire. The impact of fibromyalgia and other clinical characteristics was assessed by multivariate regression analysis.
RESULTS: More women fulfilled the criteria for fibromyalgia in the DIE group than in the non-DIE and control groups by LFESSQ-4 (31 [39%], 12 [16%], and 6 [8%], respectively; P=0.009) and LFESSQ-6 (22 [28%], 8 [11%], and 4 [5%], respectively; P=0.008). The DIE group reported significantly poorer HRQoL for all SF-36 dimensions. Women with DIE who fulfilled the criteria for fibromyalgia had lower physical component scores (-31.6; 95% confidence interval, -50.8 to -12.3; P=0.003).
CONCLUSION: The estimated prevalence of fibromyalgia was higher among women with DIE. Women with DIE and positive fibromyalgia screening had lower HRQoL.
© 2019 International Federation of Gynecology and Obstetrics.

Entities:  

Keywords:  Deep infiltrating endometriosis; Endometriosis; Fibromyalgia; London Fibromyalgia Epidemiological Study Screening Questionnaire; Pain; Quality of life; SF-36 questionnaire

Mesh:

Year:  2019        PMID: 30973964     DOI: 10.1002/ijgo.12822

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  2 in total

1.  Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020).

Authors:  Stefanie Burghaus; Sebastian D Schäfer; Matthias W Beckmann; Iris Brandes; Christian Brünahl; Radek Chvatal; Jan Drahoňovský; Wojciech Dudek; Andreas D Ebert; Christine Fahlbusch; Tanja Fehm; Peter Martin Fehr; Carolin C Hack; Winfried Häuser; Katharina Hancke; Volker Heinecke; Lars-Christian Horn; Christian Houbois; Christine Klapp; Heike Kramer; Harald Krentel; Jan Langrehr; Heike Matuschewski; Ines Mayer; Sylvia Mechsner; Andreas Müller; Armelle Müller; Michael Müller; Peter Oppelt; Thomas Papathemelis; Stefan P Renner; Dietmar Schmidt; Andreas Schüring; Karl-Werner Schweppe; Beata Seeber; Friederike Siedentopf; Horia Sirbu; Daniela Soeffge; Kerstin Weidner; Isabella Zraik; Uwe Andreas Ulrich
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-04-14       Impact factor: 2.915

2.  The COVID-19 pandemic and patients with endometriosis: A survey-based study conducted in Turkey.

Authors:  Pınar Yalçın Bahat; Cihan Kaya; Nura F T Selçuki; İbrahim Polat; Taner Usta; Engin Oral
Journal:  Int J Gynaecol Obstet       Date:  2020-09-01       Impact factor: 4.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.